Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Overactive bladder Stories

2011-10-19 06:00:00

MINNEAPOLIS, Oct. 19, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the second quarter of fiscal 2012 ended September 30, 2011, at the market close on Thursday, October 27, 2011. The Company will host a conference call to discuss these results on Thursday, October 27, 2011 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial...

2011-10-14 06:11:00

CAMPBELL, Calif., Oct. 14, 2011 /PRNewswire/ -- EMKinetics, Inc. announced today initiation of the TranStim(TM) Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder. The 120-person trial will be conducted at 10-15 US centers. Submission for CE mark and 510(k) clearance will follow the completion of the study. EMKinetics' TranStim therapy builds on the body of evidence that posterior tibial nerve stimulation (PTNS) can...

2011-08-31 15:00:00

"Imagine No IC" Research Offers Hope for Better Treatments and a Cure for Interstitial Cystitis ROCKVILLE, Md., Aug. 31, 2011/PRNewswire-USNewswire/ -- The Interstitial Cystitis Association (ICA) has issued a call for research proposals to find better treatments and a cure for interstitial cystitis (IC), a chronic, painful bladder disorder that affects at least 4 million people in the United States. Funded through the "Imagine No IC" campaign, the ICA Pilot Research Program offers...

2011-08-28 19:00:00

TOKYO, Aug. 28, 2011 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. The submissions were sent on August 24 and 26, 2011 (Europe and US, respectively). Astellas is seeking approval for this first in a new class of medicine for the indication of overactive...

2011-08-15 05:30:00

MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of two clinical studies using Uroplasty's Urgent® PC Neuromodulation System are scheduled to be presented at the International Continence Society meeting, August 29-September 2, 2011 in Glasgow, Scotland. "These data from on-going...

2011-07-21 06:00:00

MINNEAPOLIS, July 21, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the first quarter of fiscal 2012 ended June 30, 2011, at the market close on Thursday, July 28, 2011. The Company will host a conference call to discuss these results on Thursday, July 28, 2011 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and...

2011-07-18 05:30:00

MINNEAPOLIS, July 18, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms. Effective August 1, 2011, Health Care Service Corporation...

2011-07-11 06:00:00

PARSIPPANY, N.J. and EWING, N.J., July 11, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada. A New Drug Application for the oxybutynin gel product is currently under review by the Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of December 8,...

2011-05-31 05:30:00

MINNEAPOLIS, May 31, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued guidance on percutaneous tibial nerve stimulation (PTNS) for the treatment of faecal incontinence. In October 2010, NICE issued similar guidance on PTNS treatment for overactive bladder. "This NICE guidance should encourage physicians in the UK and Europe to use our Urgent® PC...

2011-05-17 14:31:00

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...